1.1Lower ascorbic acid concentration
A 10 mL fill supplies 100 mg of ascorbic acid, the same amount as a 5 mL fill at 20 mg/mL. The larger fill volume preserves the amount delivered per unit.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A 10 mL fill supplies 100 mg of ascorbic acid, the same amount as a 5 mL fill at 20 mg/mL. The larger fill volume preserves the amount delivered per unit.
Calcium disodium edetate supplies edetate with calcium already bound. Trace copper ions displace the bound calcium, reducing the free copper available to catalyze ascorbate oxidation.
Nitrogen sparging lowers dissolved oxygen before filling, and a nitrogen flush displaces air from the ampoule headspace. Flame sealing the glass neck limits oxygen entry during storage.
Sodium acetate and acetic acid form a buffer pair that takes up added acid or base. Their ratio is set in the final solution to reach pH 5.0, and the sealed container limits carbon dioxide exchange during storage.
A measured volume of concentrate is transferred aseptically into a compatible sterile infusion fluid. Mixing distributes the ascorbic acid, and the selected final volume sets its infusion concentration.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Sealed single-use ampoules contain an aqueous solution of ascorbic acid, edetate disodium, sodium metabisulfite, and an acetate buffer. A laboratory dilutes the ampoule contents into the mobile phase and analyzes the solution by liquid chromatography with ultraviolet detection. A separately prepared ascorbic acid reference establishes the expected retention time, and the ampoule solution checks retention time and detector response during routine instrument operation.
Citric acid and sodium citrate form the buffer in an aqueous solution containing ascorbic acid, edetate disodium, and a separate sodium metabisulfite antioxidant. The ratio of the citrate species sets the solution pH, and the total citrate concentration sets the buffer capacity and contributes to osmolality. A formulation study measures pH, osmolality, and ascorbic acid assay at filling and during storage to select the buffer composition.
A common bulk solution contains 25 mg/mL ascorbic acid, edetate disodium, a separate antioxidant, an acetate buffer, and water for injection. The filling line dispenses 2 mL or 4 mL into single-dose vials, yielding nominal vial contents of 50 mg or 100 mg of ascorbic acid, respectively. Each fill configuration undergoes testing for extractable volume and container closure integrity, and the stability study compares both configurations after three months at 20 to 25 °C.
Single-dose glass vials contain the buffered aqueous ascorbic acid solution with edetate disodium and a separate antioxidant. The filling line flushes the vial headspace with nitrogen immediately before stoppering and targets residual headspace oxygen of 2% by volume or less. A headspace oxygen analyzer checks sealed samples, and a three-month study at 20 to 25 °C tracks ascorbic acid content and oxidation products.
The buffered aqueous ascorbic acid solution contains edetate disodium and a separate antioxidant and is supplied in a sterile, single-use prefilled syringe. The syringe barrel and plunger dimensions match a supported syringe profile in a programmable syringe pump. The pump advances the plunger at the configured volumetric rate through a compatible administration line. Compatibility testing measures delivered volume and ascorbic acid recovery after contact with the syringe and line.
A dissolved-oxygen probe and a pH probe monitor a recirculation loop on the holding vessel for the buffered ascorbic acid solution. The controller logs both measurements by batch and pauses filling when either reading moves outside its configured range. An inline checkweigher compares filled vial masses with limits derived from the target fill volume, measured solution density, and vial tare. The batch record links sensor readings, fill checks, and rejected units to the filling run.
Ascorbic acid is dissolved in an aqueous carrier at a final concentration of 25 mg/mL. A 4 mL fill contains 100 mg of ascorbic acid.
Edetate disodium is dissolved at 0.01% w/v, or 0.1 mg/mL. The chelator binds trace metal ions such as copper and reduces the free metal available to catalyze oxidation.
Sodium metabisulfite is added at 0.10% w/v as a separate dissolved ingredient. It forms bisulfite in water, and the resulting sulfite species react with dissolved oxygen.
Water for injection dissolves the ascorbic acid and the water-soluble excipients. Additional water for injection brings the mixed batch to its specified final volume before sterile filtration and aseptic filling.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
(1) providing a fresh produce treatment comprised of water and ascorbic acid;A · US 8,647,572 B1 · ¶ 16
(ii) a chelating agent selected from edetate disodium (disodium EDTA), edetate disodium (disodium EDTA) anhydrous, edetate sodium, edetate calcium disodium, edetate calcium di sodium anhydrous, edetic acid and a mixture thereof;B · US 2020/0188478 A1 · ¶ 69
Name of Ingredient (Role of ingredient) Example-1 Example-2 Example-3 Example-4 Example-5 Example-6 Vancomycin# 5 mg/mL 5 mg/mL 5 mg/mL 5 mg/mL 5 mg/mL 5 mg/mL (Active) Sodium chloride 8 mg/mL 8 mg/mL 1 mg/mL 1 mg/mL 1 mg/mL 8 mg/mL (Tonicity modifying agent) Dextrose — — — — — — (Tonicity modifying agent) L-methioninc 20 mg/mL 40 mg/mL 40 mg/mL 40 mg/mL — 20 mg/mL (Anti-oxidant/stabilizer) Sodium hydroxide Q.S.* Q.S.* Q.S.* Q.S.* Q.S.* — (pH adjusting agent) TriethanolamineB · US 2020/0188478 A1 · ¶
Name of Ingredient (Role of ingredient) Example-7 Example-8 Example-9 Example-10 Example-11 Example-12 Vancomycin# (Active) 5 mg/mL 5 mg/mL 5 mg/mL 5 mg/mL 5 mg/mL 5 mg/mL Mannitol — — 20 mg/mL — 20 mg/mL — (Tonicity modifying agent) L-methionine 20 mg/mL — 20 mg/mL — — — (Stabilizer) Polyvinyl pyrrolidone — — — 20 mg/mL 20 mg/mL — (Stabilizer) Polyethylene glycol-400 — 20 mg/mL 20 mg/mL — 20 mg/mL — (co-solvent/solubilizer) Poloxamer — — — — — 6 mg/mL (co-solvent/solubilizerB · US 2020/0188478 A1 · ¶
(iii) a vehicle selected from water such as water for injection; and (iv) optionally a pharmaceutically acceptable excipient.B · US 2020/0188478 A1 · ¶ 69
(d) The Vancomycin formulation of the present invention is stable for prolonged time, say for example at least for three months or more. Further, no special storage conditions (such as storing at −20° C.) are required to achieve the prolonged stability.B · US 2020/0188478 A1 · ¶ 21
An empty cell means only that no passage was reproduced there.
Ascorbate compound solution is used as an anti-oxidant dip for the prevention of the browning of fruit and vegetable surfaces, and preserving the appearance, texture, crispness and color of fresh cut or minimally processed fruits and vegetables, such as apples.A · US 8,647,572 B1 · ¶ 5
Proper management via continuous or continual monitoring and control of ascorbate concentration levels in the dip tank during processing enhances the effectiveness of the ascorbate as a preservative for fresh fruit and vegetables.A · US 8,647,572 B1 · ¶ 5
Both processes may involve (i) stability concerns of the diluted solutions and (ii) dosing errors & cross contamination while diluting with diluent before administration to patient.B · US 2020/0188478 A1 · ¶ 1
It is therefore advantageous to have pre-mixed, ready-to-use injectable solution which does not require reconstitution or dilution before administration.B · US 2020/0188478 A1 · ¶ 1
patent.fyi, US 2026/0355149 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355149/, SHA-256 2eb164297e1e314502320393aad6205fb8cef54b95fcde4630f2cab30c513730